Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANCN

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

Anchiano Therapeutics logo

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

Key Stats

Today's Range
$3.03
$3.49
50-Day Range
$2.82
$59.00
52-Week Range
$0.51
$10.55
Volume
336,199 shs
Average Volume
3.15 million shs
Market Capitalization
$24.34 million
P/E Ratio
21.87
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ANCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANCN Stock News Headlines

ITeos Therapeutics Inc Ordinary Shares
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
ENDV Endonovo Therapeutics, Inc.
See More Headlines

ANCN Stock Analysis - Frequently Asked Questions

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) issued its earnings results on Monday, August, 5th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.12.

Anchiano Therapeutics (ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anchiano Therapeutics investors own include BioCryst Pharmaceuticals (BCRX), Bionano Genomics (BNGO), Cheniere Energy (LNG), Ocugen (OCGN), Agenus (AGEN), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN).

Company Calendar

Last Earnings
8/05/2019
Today
10/11/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANCN
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.46)
Trailing P/E Ratio
21.87
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.12 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
36.08%
Return on Assets
27.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.25
Quick Ratio
3.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.01 per share
Price / Book
1.63

Miscellaneous

Outstanding Shares
7,420,000
Free Float
N/A
Market Cap
$24.34 million
Optionable
Not Optionable
Beta
0.93
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ANCN) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners